Chi-Med To Host R&D Briefings on March 29 & 30, 2017

LONDON–(BUSINESS WIRE)– Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today
announces that it will host Research & Development (“R&D”) briefings in
London and New York to provide an overview of the Company’s clinical
pipeline of eight novel drug candidates. The events for analysts and
investors will take place in London on Wednesday, March 29, and in New
York on Thursday, March 30, 2017.

Chi-Med is a China-based biopharmaceutical company focused on
discovering and developing targeted therapies for oncology and
immunological diseases for the global market. The Company has 30 ongoing
clinical trials with eight novel drug candidates, which are expected to
report a steady flow of pivotal Phase III trial results from this year
onwards. Chi-Med’s first drug is targeted to launch next year in China.

The Chi-Med management team will outline the Company’s R&D strategy and
discuss its drug candidate pipeline during the briefings.

The briefing on Wednesday, March 29, 2017 in London will begin with a
keynote presentation from Dr Susan Galbraith, Vice President of Oncology
Innovative Medicines and Early Development at AstraZeneca.

Mr Christian Hogg, Chief Executive Officer; Dr Weiguo Su, Executive Vice
President and Chief Scientific Officer; Dr Zhenping Wu, Senior Vice
President of Pharmaceutical Sciences; and Dr May Wang, Senior Vice
President of Business Development & Strategic Alliances, will be
presenting on Chi-Med’s research & development and partnering
activities. Chi-Med currently has partnerships with AstraZeneca, Eli
Lilly and Company and Nestlé Health Science S.A.

To register for the London briefing, please contact Dr Marine Perrier by
telephone at +44 20 7282 1068 or by email at marine.perrier@citigatedr.co.uk.

To register for the New York briefing, please contact Matt Beck by
telephone at +1 646 378 2933 or by email at mbeck@troutgroup.com.

No new material trading or financial information will be disseminated at
the meeting. Following the meeting, the presentations will be made
available at http://www.chi-med.com/news/.

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches,
develops, manufactures and sells pharmaceuticals and healthcare
products. Its Innovation Platform, Hutchison MediPharma Limited, focuses
on discovering and developing innovative therapeutics in oncology and
autoimmune diseases for the global market. Its Commercial Platform
manufactures, markets, and distributes prescription drugs and consumer
health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison
Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.

Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of the « safe harbor » provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements
reflect Chi-Med’s current expectations regarding future events,
including its expectations for the clinical development of savolitinib,
fruquintinib, sulfatinib, epitinib, theliatinib, HMPL-523, HMPL-689,
HMPL-453 and other drug research and development projects, including
plans for clinical studies, its expectations as to whether such studies
would meet their primary or secondary endpoints, and its expectations as
to the timing of the completion and the release of results from such
studies. Forward-looking statements involve risks and
uncertainties. Such risks and uncertainties include, among other
things, assumptions regarding enrollment rates, timing and availability
of subjects meeting a study’s inclusion and exclusion criteria, changes
to clinical protocols or regulatory requirements, unexpected adverse
events or safety issues, the ability of drug candidate sulfatinib to
meet the primary or secondary endpoint of a study, to obtain regulatory
approval in different jurisdictions, to gain commercial acceptance after
obtaining regulatory approval, the potential market of sulfatinib for a
targeted indication and the sufficiency of funding. Existing and
prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. For
further discussion of these and other risks, see Chi-Med’s filings with
the U.S. Securities and Exchange Commission and on AIM. Chi-Med
undertakes no obligation to update or revise the information contained
in this press release, whether as a result of new information, future
events or circumstances or otherwise.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170321005791/en/